Cellect Biotechnology Ltd APOP shares are trading lower on Friday, after the company reported fourth-quarter earnings results.
Cellect is a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel.
Cellect Biotechnology shares are trading down 8.63% at $1.80 on Friday. The stock has a 52-week high of $6.89 and a 52-week low of 40 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: Newswhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in